» Articles » PMID: 12644585

Involvement of Organic Cation Transporter 1 in the Lactic Acidosis Caused by Metformin

Overview
Journal Mol Pharmacol
Date 2003 Mar 20
PMID 12644585
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Biguanides are a class of drugs widely used as oral antihyperglycemic agents for the treatment of type 2 diabetes mellitus, but they are associated with lactic acidosis, a lethal side effect. We reported previously that biguanides are good substrates of rat organic cation transporter 1 (Oct1; Slc22a1) and, using Oct1(-/-) mice, that mouse Oct1 is responsible for the hepatic uptake of a biguanide, metformin. In the present study, we investigated whether the liver is the key organ for the lactic acidosis. When mice were given metformin, the blood lactate concentration significantly increased in the wild-type mice, whereas only a slight increase was observed in Oct1(-/-) mice. The plasma concentration of metformin exhibited similar time profiles between the wild-type and Oct1(-/-) mice, suggesting that the liver is the key organ responsible for the lactic acidosis. Furthermore, the extent of the increase in blood lactate caused by three different biguanides (metformin, buformin, and phenformin) was compared with the abilities to reduce oxygen consumption in isolated rat hepatocytes. When rats were given each of these biguanides, the lactate concentration increased significantly. This effect was dose-dependent, and the EC(50) values of metformin, buformin, and phenformin were 734, 119, and 4.97 microM, respectively. All of these biguanides reduced the oxygen consumption by isolated rat hepatocytes in a concentration-dependent manner. When the concentration required to reduce the oxygen consumption to 75% of the control value (from 0.40 to 0.29 micromol/min/mg protein) was compared with the EC(50) value obtained in vivo, a clear correlation was observed among the three biguanides, suggesting that oxygen consumption in isolated rat hepatocytes can be used as an index of the incidence of lactic acidosis.

Citing Articles

OCT1 (SLC22A1) transporter kinetics and regulation in primary human hepatocyte 3D spheroids.

Mickols E, Meyer A, Handin N, Stuwe M, Eriksson J, Rudfeldt J Sci Rep. 2024; 14(1):17334.

PMID: 39068198 PMC: 11283471. DOI: 10.1038/s41598-024-67192-6.


Case Report: Late-Onset Mitochondrial Disease Uncovered by Metformin Use in a Patient With Acute Verbal Auditory Agnosia.

Lin W, Yang I, Cheng H, Lin H Front Neurol. 2022; 13:863047.

PMID: 35401420 PMC: 8990297. DOI: 10.3389/fneur.2022.863047.


Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.

Theurey P, Vial G, Fontaine E, Monternier P, Fouqueray P, Bolze S Physiol Rep. 2022; 10(5):e15151.

PMID: 35274817 PMC: 8915386. DOI: 10.14814/phy2.15151.


Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment.

Yip T, Chan R, Wong V, Tse Y, Liang L, Hui V Health Sci Rep. 2021; 4(3):e352.

PMID: 34401527 PMC: 8358231. DOI: 10.1002/hsr2.352.


OCT1 Polyspecificity-Friend or Foe?.

Meyer M, Tzvetkov M Front Pharmacol. 2021; 12:698153.

PMID: 34149437 PMC: 8206551. DOI: 10.3389/fphar.2021.698153.